GlassScriptPhysician profile
Nora L Bailey
NPI 1699191908
$3,321.85
in general payments reported to CMS, 2019-2025
21 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $853 · 2023: $773 · 2024: $1,478 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $1,000.00 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $417.72 | 2022-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.12 | 2021-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $192.73 | 2021-2022 | |
| Corium, LLC | $191.88 | 2022-2024 | Azstarys |
| Alkermes, INC. | $163.23 | 2022-2024 | Lybalvi, Aristada |
| Neos Therapeutics, LP | $151.88 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Axsome Therapeutics, INC. | $142.77 | 2022-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $127.63 | 2023-2024 | Qelbree, Qelbree |
| Abbvie INC. | $104.55 | 2023-2025 | Vraylar |
| Bausch Health US, LLC | $104.46 | 2022-2024 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $95.22 | 2022-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $91.76 | 2022-2023 | Uzedy, Austedo |
| Lundbeck LLC | $79.67 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $77.25 | 2022-2024 | Invega Sustenna, Invega Trinza, Invega |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $41.16 | 2022 | |
| Vanda Pharmaceuticals INC. | $34.25 | 2022 | |
| Tris Pharma INC | $33.00 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $28.98 | 2022 | |
| Idorsia Pharmaceuticals US INC | $24.43 | 2022 | |
| C2n Diagnostics, LLC | $21.16 | 2025 | Precivityad2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.